葡萄膜炎：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

市場概覽

• 中國葡萄膜炎市場預計將從 2025 年的約 8,070 萬美元成長到 2035 年的約 9,730 萬美元，呈現逐步擴張的態勢。
• 市場成長受以下因素支撐：
• 生物製劑和非類固醇免疫調節療法的廣泛應用
• 改善慢性病和復發性疾病的診斷和長期管理
• 市場規模的擴大是由治療週期延長和先進眼科治療方法的日益普及所推動的。
• 未來市場成長將取決於標靶免疫療法的發展、更安全的長期治療策略以及難治性葡萄膜炎治療的改善。

葡萄膜炎概述

葡萄膜炎是一組涉及葡萄膜（包括虹膜、睫狀體和脈絡膜）的異質性眼內發炎性疾病，根據解剖學特徵可分為前葡萄膜炎、中間葡萄膜炎、後葡萄膜炎或全葡萄膜炎。此病可由皰疹病毒、結核病、弓形蟲病和梅毒等感染因素引起，也可由非感染性免疫介導機制引起，後者常與白塞病、類肉瘤病、幼年特發性關節炎和脊柱關節炎等系統性自體免疫疾病有關。臨床症狀因病灶部位而異，但通常包括眼痛、眼紅、畏光、視力下降和飛蚊症。

慢性或控制不佳的葡萄膜炎可導致嚴重的、威脅視力的併發症，包括白內障、青光眼、黃斑部水腫和視網膜損傷。診斷包括全面的眼科檢查，並藉助光學同調斷層掃描（OCT）和螢光造影等影像學技術，以及針對性的全身檢查，以確定潛在的感染或自體免疫病因。

皮質類固醇仍是治療非感染性葡萄膜炎的基石，可依疾病嚴重程度和病變部位，以局部、眼周或全身給藥。免疫抑制劑，如胺基甲基葉酸、Azathioprine和黴酚酸酯，常用於慢性或復發性病例，而生物製藥，如Adalimumab，擴大用於難治性非感染性葡萄膜炎。儘管治療方法不斷進步，但發炎復發、長期使用皮質類固醇的毒性以及不可逆性視力損傷的風險仍然是尚未解決的主要臨床挑戰。

主要亮點

• 預計到 2025 年，中國葡萄膜炎患者總數將約為 3,611,621 人，到 2035 年將約為 3,754,973 人，反映出該疾病的負擔日益加重。
• 在已確診的患者族群中，前葡萄膜炎仍是最常見的臨床亞型。
• 慢性及復發性發炎仍然是長期視力障礙和生活品質下降的主要原因。
• 免疫抑制療法和生物製藥的廣泛應用改善了難治性非感染性葡萄膜炎的治療。
• 早期診斷和多學科疾病管理對於預防不可逆的眼部併發症仍然至關重要。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Priovant Therapeutics, Inc.
• Changchun GeneScience Pharmaceutical Co., Ltd.
• Eli Lilly and Company

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者人數
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 主要治療方法概述及KOL洞察
• 新興治療方法
• 重點
• 值得關注的後期新治療方法－概述、市場上市預期及KOL洞察
• 值得關注的早期管道

第6章：未滿足的需求與目標產品分析

• 主要未滿足的需求及其未來透過新興治療方法實現的可能性
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Uveitis Disease Market Outlook

Thelansis's "Uveitis Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uveitis Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Uveitis Disease Overview

Uveitis is a heterogeneous group of intraocular inflammatory disorders affecting the uveal tract, including the iris, ciliary body, and choroid, and is classified anatomically as anterior, intermediate, posterior, or panuveitis. The disease may result from infectious causes such as herpesviruses, tuberculosis, toxoplasmosis, and syphilis, or from non-infectious immune-mediated mechanisms frequently associated with systemic autoimmune disorders including Behcet disease, sarcoidosis, juvenile idiopathic arthritis, and spondyloarthropathies. Clinical presentation varies by anatomical involvement and commonly includes eye pain, redness, photophobia, blurred vision, and floaters.

Chronic or inadequately controlled uveitis can lead to severe vision-threatening complications including cataract, glaucoma, cystoid macular edema, and retinal damage. Diagnosis involves comprehensive ophthalmic examination supported by imaging techniques such as optical coherence tomography and fluorescein angiography, alongside targeted systemic investigations to identify underlying infectious or autoimmune etiologies.

Corticosteroids remain the cornerstone of treatment for non-infectious uveitis and may be administered topically, periocularly, or systemically depending on disease severity and location. Immunosuppressive therapies including methotrexate, azathioprine, and mycophenolate are commonly used in chronic or recurrent disease, while biologics such as adalimumab are increasingly utilized in refractory non-infectious uveitis. Despite therapeutic advances, recurrent inflammation, long-term corticosteroid toxicity, and risk of irreversible visual impairment continue to represent major unmet clinical challenges.

Key Highlights

• In China, total prevalent uveitis cases are projected to increase from approximately 3,611,621 in 2025 to nearly 3,754,973 by 2035, reflecting a growing disease burden.
• Anterior uveitis remains the most common clinical subtype across diagnosed patient populations.
• Chronic and recurrent inflammation continues to contribute significantly to long-term visual impairment and reduced quality of life.
• Increasing use of immunosuppressive therapies and biologics is improving disease control in refractory non-infectious uveitis.
• Early diagnosis and multidisciplinary disease management remain critical to preventing irreversible ocular complications.

Market Overview

• The China uveitis market is projected to grow from approximately $80.70 MN in 2025 to nearly $97.30 MN by 2035, reflecting moderate market expansion.
• Market growth is supported by:
• Increasing adoption of biologics and steroid-sparing immunomodulatory therapies
• Improved diagnosis and long-term management of chronic and recurrent disease
• Market value growth is driven by rising treatment duration and increasing utilization of advanced ophthalmic therapies.
• Future market growth will depend on development of targeted immunotherapies, safer long-term treatment strategies, and improved management of refractory uveitis.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Priovant Therapeutics, Inc.
• Changchun GeneScience Pharmaceutical Co., Ltd.
• Eli Lilly and Company

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)